Key Documents

View All Documentation

LY255283

Name: LY255283
Brand: SIGMA

≥98% (HPLC), powder

Synonym(s):

1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₁₉H₂₈N₄O₃

CAS Number:

117690-79-6

Molecular Weight:

360.45

NACRES:

NA.77

PubChem Substance ID:

329817396

UNSPSC Code:

12352204

MDL number:

MFCD00876422

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

To inquire about this product L1920, please contact your local Merck office or dealer. Contact Technical Service

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

off-white to light yellow

solubility

DMSO: >20 mg/mL

originator

Eli Lilly

storage temp.

−20°C

SMILES string

CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2

InChI

1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)

InChI key

WCGXJPFHTHQNJL-UHFFFAOYSA-N

Description

Application

LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils.[1] LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.[1]

Biochem/physiol Actions

LY255283 is a competitive leukotriene B₄ receptor antagonist, specific to the BLT2 receptor subtype.

LY255283 is a competitive leukotriene B₄ receptor antagonist, with an IC₅₀ of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC₅₀ values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	S8822	SML1391	SML1276
Sigma-Aldrich L1920 LY255283	Sigma-Aldrich S8822 SB-525334	Sigma-Aldrich SML1391 Olmesartan medoxomil	Sigma-Aldrich SML1276 BAZ2-ICR
form powder	form solid	form powder	form powder
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. −20°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: >20 mg/mL	solubility DMSO: ≥20 mg/mL	solubility DMSO: 10 mg/mL, clear	solubility DMSO: 10 mg/mL, clear
originator Eli Lilly	originator GlaxoSmithKline	originator -	originator -

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

069K4605V

069K4605

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats.

D G Souza et al.

European journal of pharmacology, 403(1-2), 121-128 (2000-09-02)

Reperfusion of ischemic vascular beds may lead to recruitment and activation of leukocytes, release of mediators of the inflammatory process and further injury to the affected vascular bed and to remote sites. Neutrophils appear to play a major role in

Commonly used leukotriene B4 receptor antagonists possess intrinsic activity as agonists in human endothelial cells: Effects on calcium transients, adhesive events and mediator release.

Anne-Sofie Johansson et al.

Prostaglandins, leukotrienes, and essential fatty acids, 84(3-4), 109-112 (2010-12-25)

Leukotriene B4 (LTB4), a potent chemotactic and immune-modulating lipid mediator, signals via two receptors, BLT1 and BLT2, leading to pro-inflammatory responses in phagocytes. Recently, we reported that BLT1 is the predominating BLT on human umbilical vein endothelial cells (HUVEC) and

LY255283, a novel leukotriene B4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs.

P S Wollert et al.

Surgery, 114(2), 191-198 (1993-08-01)

Polymorphonuclear neutrophils (PMNs) have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). Because leukotriene B4 (LTB4) is a potent activator of PMNs, we sought to determine whether LY255283, an LTB4 receptor antagonist, could block PMN activation

View All Related Papers

Global Trade Item Number

SKU	GTIN
L1920-5MG	04061833024263
L1920-25MG	04061833024256

Questions

Reviews

No rating value